Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind Controlled Trial to Assess the Impact of BLa80 on the Intestinal Health of Individuals Who Consume Alcohol

NCT06216587 is registered in ClinicalTrials.gov with Wecare Probiotics Co., Ltd. as lead sponsor.

NCT NCT06216587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06216587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind Controlled Trial to Assess the Impact of BLa80 on the Intestinal Health of Individuals Who Consume Alcohol
Lead sponsor
Wecare Probiotics Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
March 20, 2024
Completion date
July 14, 2024
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol drinking, adult disease